Skip to main content
Erschienen in: Pathology & Oncology Research 3/2009

01.09.2009 | Original Paper

Analysis of p53 Gene Polymorphisms and Protein Over-expression in Patients with Breast Cancer

verfasst von: Mustafa Akkiprik, Ozgur Sonmez, Bahadir M. Gulluoglu, Hale B. Caglar, Handan Kaya, Pakize Demirkalem, Ufuk Abacioglu, Meric Sengoz, Aydin Sav, Ayse Ozer

Erschienen in: Pathology & Oncology Research | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

p53 polymorphic variants play an important role in the determination of tumor phenotype and characteristics in breast cancer. In this study, we examined three common polymorphisms in p53 gene and their haplotype combinations to assess their potential association with inherited predisposition to breast cancer development, in relations with the protein over-expression and patients’ demographic data. A total of 99 patients with breast cancer and 107 age-matched healthy controls were included in the study. Genotypes were determined using PCR-RFLP and DNA sequencing techniques. Evaluation of p53 protein over-expression was also examined by immunohistochemistry. Among three polymorphisms, increased codon 72 Pro allele frequency (p = 0.0067) and the presence of Pro allele were found to be significantly associated with breast cancer (p = 0.013). A significant risk was also found in subjects with combinations of specific haplotypes and genotypes. Most of breast cancer women especially younger than 50 years carry at least one p53 polymorphism (p = 0.001). There was no any association between these three p53 polymorphisms and the protein over-expression, separately or in interaction, with breast cancer. In conclusion, presence of proline allele at codon 72 alone, and its special combinations with other two polymorphisms appear to be a significant risk factor for breast cancer. Determination of well-known p53 polymorphisms might be a good predictor for breast cancer development especially in women younger than 50 years.
Literatur
1.
Zurück zum Zitat Dunning AM, Healey CS, Pharoah PD et al (1999) A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 8:843–854PubMed Dunning AM, Healey CS, Pharoah PD et al (1999) A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 8:843–854PubMed
2.
3.
Zurück zum Zitat Nigro JM, Baker SJ, Preisinger AC et al (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705–708CrossRefPubMed Nigro JM, Baker SJ, Preisinger AC et al (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705–708CrossRefPubMed
4.
Zurück zum Zitat Olivier M, Langerod A, Carrieri P et al (2006) The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12:1157–1167CrossRefPubMed Olivier M, Langerod A, Carrieri P et al (2006) The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12:1157–1167CrossRefPubMed
5.
Zurück zum Zitat Olivier M, Eeles R, Hollstein M et al (2002) The IARC TP53 Database: new online mutation analysis and recommendations to users. Hum Mutat 19:607–614CrossRefPubMed Olivier M, Eeles R, Hollstein M et al (2002) The IARC TP53 Database: new online mutation analysis and recommendations to users. Hum Mutat 19:607–614CrossRefPubMed
6.
Zurück zum Zitat Weston A, Pan CF, Ksieski HB et al (1997) p53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev 6:105–112PubMed Weston A, Pan CF, Ksieski HB et al (1997) p53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev 6:105–112PubMed
7.
Zurück zum Zitat Wang-Gohrke S, Rebbeck TR, Besenfelder W et al (1998) p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res 18:2095–2099PubMed Wang-Gohrke S, Rebbeck TR, Besenfelder W et al (1998) p53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res 18:2095–2099PubMed
8.
Zurück zum Zitat Papadakis EN, Dokianakis DN, Spandidos DA (2000) p53 codon 72 polymorphisms as a risk factor in the development of breast cancer. Mol Cell Bio Res Comm 3:389–392CrossRef Papadakis EN, Dokianakis DN, Spandidos DA (2000) p53 codon 72 polymorphisms as a risk factor in the development of breast cancer. Mol Cell Bio Res Comm 3:389–392CrossRef
9.
Zurück zum Zitat Kalemi TG, Lambropoulos AF, Gueorguiev M et al (2005) The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett 222:57–65CrossRefPubMed Kalemi TG, Lambropoulos AF, Gueorguiev M et al (2005) The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett 222:57–65CrossRefPubMed
10.
Zurück zum Zitat Sjalander A, Birgander R, Hallmans G et al (1996) p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17:1313–1316CrossRefPubMed Sjalander A, Birgander R, Hallmans G et al (1996) p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17:1313–1316CrossRefPubMed
11.
Zurück zum Zitat Dumont P, Leu JIJ, Pietra ACD et al (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357–365CrossRefPubMed Dumont P, Leu JIJ, Pietra ACD et al (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357–365CrossRefPubMed
12.
Zurück zum Zitat Marin MC, Jost CA, Brooks LA et al (2000) A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25:47–54CrossRefPubMed Marin MC, Jost CA, Brooks LA et al (2000) A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25:47–54CrossRefPubMed
13.
Zurück zum Zitat Gemignani F, Moreno V, Landi S et al (2004) A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 23:1954–1956CrossRefPubMed Gemignani F, Moreno V, Landi S et al (2004) A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 23:1954–1956CrossRefPubMed
14.
Zurück zum Zitat Peller S, Kopilova Y, Slutzki S et al (1995) A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility. DNA Cell Biol 14:983–990CrossRefPubMed Peller S, Kopilova Y, Slutzki S et al (1995) A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility. DNA Cell Biol 14:983–990CrossRefPubMed
15.
Zurück zum Zitat Weston A, Wolff MS, Morabia A (1998) True extended haplotypes of p53: indicators of breast cancer risk. Cancer Genet Cytogenet 102:153–154CrossRefPubMed Weston A, Wolff MS, Morabia A (1998) True extended haplotypes of p53: indicators of breast cancer risk. Cancer Genet Cytogenet 102:153–154CrossRefPubMed
16.
Zurück zum Zitat Sjalander A, Birgander R, Kivela A et al (1995) p53 polymorphisms and haplotypes in different ethnic groups. Hum Hered 45:144–149CrossRefPubMed Sjalander A, Birgander R, Kivela A et al (1995) p53 polymorphisms and haplotypes in different ethnic groups. Hum Hered 45:144–149CrossRefPubMed
17.
Zurück zum Zitat Wu X, Zhao H, Amos CI et al (2002) p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 94:681–690PubMed Wu X, Zhao H, Amos CI et al (2002) p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 94:681–690PubMed
18.
Zurück zum Zitat Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer: experience from a long study with long term follow-up. Histopathology 19:403–410CrossRefPubMed Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer: experience from a long study with long term follow-up. Histopathology 19:403–410CrossRefPubMed
19.
Zurück zum Zitat Singletary SE, Allred C, Ashley P et al (2002) Revision of the American Joint Committee on Cancer Staging System for breast cancer. J Clin Oncol 20:3628–3636CrossRefPubMed Singletary SE, Allred C, Ashley P et al (2002) Revision of the American Joint Committee on Cancer Staging System for breast cancer. J Clin Oncol 20:3628–3636CrossRefPubMed
20.
Zurück zum Zitat Soong R, Iacopetta BJ (1997) A rapid and nonisotopic method for the screening and sequencing of p53 gene mutations in formalin-fixed, paraffin-embedded tumors. Mod Pathol 10:252–258PubMed Soong R, Iacopetta BJ (1997) A rapid and nonisotopic method for the screening and sequencing of p53 gene mutations in formalin-fixed, paraffin-embedded tumors. Mod Pathol 10:252–258PubMed
21.
Zurück zum Zitat John SW, Weitzner G, Rozen R et al (1991) A rapid procedure for extracting genomic DNA from leukocytes. Nucleic Acid Res 19:408CrossRefPubMed John SW, Weitzner G, Rozen R et al (1991) A rapid procedure for extracting genomic DNA from leukocytes. Nucleic Acid Res 19:408CrossRefPubMed
23.
Zurück zum Zitat Khadang B, Fattahi MJ, Talei A et al (2007) Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet 173:38–42CrossRefPubMed Khadang B, Fattahi MJ, Talei A et al (2007) Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet 173:38–42CrossRefPubMed
24.
Zurück zum Zitat Franekova M, Zubor P, Stanclova A et al (2007) Association of p53 polymorphisms with breast cancer: a case-control study in Slovak population. Neoplasma 54:155–161PubMed Franekova M, Zubor P, Stanclova A et al (2007) Association of p53 polymorphisms with breast cancer: a case-control study in Slovak population. Neoplasma 54:155–161PubMed
25.
Zurück zum Zitat Buyru N, Tigli H, Dalay N (2003) p53 codon 72 polymorphism in breast cancer. Oncol Rep 10:711–714PubMed Buyru N, Tigli H, Dalay N (2003) p53 codon 72 polymorphism in breast cancer. Oncol Rep 10:711–714PubMed
26.
Zurück zum Zitat Langerod A, Bukholm IRK, Bregard A et al (2002) The TP53 Codon 72 polymorphism may affect the function of TP53 mutation in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 11:1684–1688PubMed Langerod A, Bukholm IRK, Bregard A et al (2002) The TP53 Codon 72 polymorphism may affect the function of TP53 mutation in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 11:1684–1688PubMed
27.
Zurück zum Zitat Suspitsin EN, Buslov KG, Grigoriev MY et al (2003) Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int J Cancer 103:431–433CrossRefPubMed Suspitsin EN, Buslov KG, Grigoriev MY et al (2003) Evidence against involvement of p53 polymorphism in breast cancer predisposition. Int J Cancer 103:431–433CrossRefPubMed
28.
Zurück zum Zitat Wang-Gohrke S, Becher H, Kreienberg R et al (2002) Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk or breast cancer by the age of 50 years. Pharmacogenetics 12:269–272CrossRefPubMed Wang-Gohrke S, Becher H, Kreienberg R et al (2002) Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk or breast cancer by the age of 50 years. Pharmacogenetics 12:269–272CrossRefPubMed
29.
Zurück zum Zitat Wegman P, Stal O, Askmalm MS et al (2006) p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients. Pharmacogenet Genomics 16:347–351CrossRefPubMed Wegman P, Stal O, Askmalm MS et al (2006) p53 polymorphic variants at codon 72 and the outcome of therapy in randomized breast cancer patients. Pharmacogenet Genomics 16:347–351CrossRefPubMed
30.
Zurück zum Zitat Tan XL, Popanda O, Ambrosone CB et al (2006) Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients. Breast Cancer Res Treat 97:255–262CrossRefPubMed Tan XL, Popanda O, Ambrosone CB et al (2006) Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients. Breast Cancer Res Treat 97:255–262CrossRefPubMed
31.
Zurück zum Zitat Costa S, Pinto D, Pereira D et al (2008) Importance of TP53 codon 72 and intron 3 duplication 16 bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer 8:32CrossRefPubMed Costa S, Pinto D, Pereira D et al (2008) Importance of TP53 codon 72 and intron 3 duplication 16 bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer 8:32CrossRefPubMed
32.
Zurück zum Zitat Bartley AN, Ross DW (2002) Validation of p53 immunohistochemistry as a prognostic factor in breast cancer in clinical practice. Arch Pathol Lab Med 126:456–458PubMed Bartley AN, Ross DW (2002) Validation of p53 immunohistochemistry as a prognostic factor in breast cancer in clinical practice. Arch Pathol Lab Med 126:456–458PubMed
33.
Zurück zum Zitat Rolland P, Spendlove I, Madjid Z et al (2007) The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer. Int J Cancer 120:1311–1317CrossRefPubMed Rolland P, Spendlove I, Madjid Z et al (2007) The p53 positive Bcl-2 negative phenotype is an independent marker of prognosis in breast cancer. Int J Cancer 120:1311–1317CrossRefPubMed
34.
Zurück zum Zitat Yamashita H, Toyama T, Nishio M et al (2006) p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res 8:R48CrossRefPubMed Yamashita H, Toyama T, Nishio M et al (2006) p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res 8:R48CrossRefPubMed
35.
Zurück zum Zitat Roos MA, de Bock GH, de Vries J et al (2007) p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast. J Surg Res 140:109–114CrossRefPubMed Roos MA, de Bock GH, de Vries J et al (2007) p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast. J Surg Res 140:109–114CrossRefPubMed
36.
Zurück zum Zitat Kai K, Nishimura R, Arima N et al (2006) p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study. Int J Clin Oncol 11:426–433CrossRefPubMed Kai K, Nishimura R, Arima N et al (2006) p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study. Int J Clin Oncol 11:426–433CrossRefPubMed
37.
Zurück zum Zitat Gammon MD, Hibshoosh H, Terry MB et al (1999) Cigarette smoking and other risk factors in relation to p53 expression in breast cancer among young women. Cancer Epidemiol Biomarkers Prev 8:255–263PubMed Gammon MD, Hibshoosh H, Terry MB et al (1999) Cigarette smoking and other risk factors in relation to p53 expression in breast cancer among young women. Cancer Epidemiol Biomarkers Prev 8:255–263PubMed
Metadaten
Titel
Analysis of p53 Gene Polymorphisms and Protein Over-expression in Patients with Breast Cancer
verfasst von
Mustafa Akkiprik
Ozgur Sonmez
Bahadir M. Gulluoglu
Hale B. Caglar
Handan Kaya
Pakize Demirkalem
Ufuk Abacioglu
Meric Sengoz
Aydin Sav
Ayse Ozer
Publikationsdatum
01.09.2009
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 3/2009
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-008-9129-6

Weitere Artikel der Ausgabe 3/2009

Pathology & Oncology Research 3/2009 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.